Subcontracting Opportunities
Subcontracting allows small and disadvantaged businesses to substantially impact the federal procurement preference programs. Due to legislative mandates, federal prime contractors award billions of subcontracting dollars annually to small businesses — Small Business Subcontracting Plan requirements set forth in their contracts include requirements to track participation by veteran-owned, service-disabled veteran-owned, HUBZone, disadvantaged, and women-owned businesses.
USASpending.gov provides information on organizations who have a prime contractor relationship with the NCI. The current Frederick National Laboratory for Cancer Research (FNLCR) prime contractor has significant subcontracting opportunities — see FNLCR Acquisitions for further information.
NCI also maintains a list of its active Indefinite Delivery/Indefinite Quantity (ID/IQ) Prime Contractors. NCI encourages businesses to network and establish teaming arrangements to support these contracting vehicles, which are used to place a variety of orders for supplies and services through processes that do not involve public posting after the base ID/IQ contract(s) have been awarded.
| Contract Name(s) | Contract Specialist | Title & Brief Description From Article B.1. | Base Period of Performance (Start-End Dates) |
|---|---|---|---|
| Universite Laval | Reyes Rodriguez | Services to determine serum concentrations of samples collected by the Hormonal and Reproductive Epidemiology Branch (HREB). |
9/1/2015 - 8/31/2020 |
| Datawaves | Miguel Diaz | Technology Transfer Center TIMS database Maintenance and Upgrades | 9/20/2015 - 9/19/2020 |
| Repeat Diagnostics, Inc. | Miguel Diaz | Laboratory Testing Services of Telomere Length Assays for the Inherited Bone Marrow Failure Study | 9/20/2015 - 9/19/2020 |
| ASTERAND US ACQUISITION CORP | Mary Muir | Tissue source site for CPTAC Program | 9/22/2015 - 9/21/2020 |
| Artificial Intelligence in Medicine | Reyes Rodriguez | Surveillance Epidemiology and End Results (SEER) Electronic Data Capture Software Support and Installations | 9/26/2015 - 9/25/2020 |
| BIOMATRIX | Mary Muir | Tissue source site for CPTAC Program | 9/29/2015 - 9/28/2020 |
| GLOBAL BIOCLINICAL | Mary Muir | Tissue source site for CPTAC Program | 9/29/2015 - 9/28/2020 |
| Evotec (US), Inc. | Mike Collins | Title: Chemical Biology Consortium Screening Libraries Center/ Brief Description: Store and maintain the CBCSLC approximately 135,000 small molecule screening collections | 9/30/2015 - 9/29/2020 |
| 22nd Century Technologies Inc. | Christine Biser | SharePoint Maintenance & Support Services (NCCIH & NCI) | 10/17/2015 - 10/16/2020 |
| IIMO (POLAND) | Mary Muir | Tissue source site for CPTAC Program | 12/30/2015 - 12/29/2020 |
| INTERNATIONAL GENOMICS CONSORTIUM | Mary Muir | Tissue source site for CPTAC Program | 1/15/2016 - 1/14/2021 |
| ANALYTICAL BIOLOGICAL SERVICES | Mary Muir | Tissue source site for CPTAC Program | 1/19/2016 - 1/18/2021 |
| BEAUMONT HEALTH | Mary Muir | Tissue source site for CPTAC Program | 2/24/2016 - 2/23/2021 |
| BOSTON MEDICAL CENTER | Mary Muir | Tissue source site for CPTAC Program | 2/24/2016 - 2/23/2021 |
| BIOPARTNERS | Mary Muir | Tissue source site for CPTAC Program | 2/24/2016 - 2/23/2021 |
| Westat, Inc | Linda Park | The Contractor shall provide support for centralized follow-up of participants from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening and the National Lung Screening (NLST) Trials. The PLCO was designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers. The National Lung Screening Trial (NLST) was a randomized controlled trial designed to determine whether screening for lung cancer with low-dose helical computed tomography (CT) reduces mortality from lung cancer in high-risk individuals relative to screening with chest radiography. | 3/1/2016 - 2/28/2021 |
| Fisher BioServices Inc | Lexi Hudak | This IDIQ supports the NCI's Chemotherapeutic Agents Repository (NCI-CAR). This contract 1) supports compound acquisition activities related to the DTP anticancer pre-clinical drug evaluation program which seeks to identify new small molecule therapeutic agents and 2) distributes chemicals to intramural and extramural investigators for research purposes. Primary tasks are receipt, registration, storage, analysis, arraying and distribution of small molecules and purified natural products. This contract is also responsible for providing an informational interface with NCI and external investigators that are submitting or requesting research compounds; for updating of the chemical database which includes chemical, inventory, receiving and shipping information; systematic file and record keeping of both current and archival information related to Repository activities; and reacquisition of samples for continued chemical and biological studies. | 3/1/2016 - 2/28/2021 |
| CEDARS-SINAI MEDICAL CENTER | Mary Muir | Tissue source site for CPTAC Program | 3/2/2016 - 3/1/2021 |
| U. OF CALIFORNIA SAN DIEGO | Mary Muir | Tissue source site for CPTAC Program | 3/23/2016 - 3/22/2021 |
| North American Association of Central Cancer Registries (NAACCR) | Kate Muir | The objective of this contract is provide support to the North American Association of Central Cancer Registries (NMCCR) in order to make the National Cancer lnstitute's (NCI) cancer surveillance program more responsive to the needs of the division, institute, and nation, and more integrated with other partners within the national cancer surveillance enterprise.This contract focuses on three specific areas: (1) Strengthening the national capacity for collecting, analyzing, and using comparable cancer registry data for cancer surveillance and research. (2) Developing and improving methods for assessing the quality and comparability of cancer registry data. This includes, but is not limited to timeliness, completeness, and accuracy. (3) Improving the efficiency and quality of registry operationsthrough promoting established standards, disseminating technical information, and facilitating collaboration among Federal, state, provincial and local registry professionals. |
7/1/2014 - 6/30/2021 |
| IITRI | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2014 - 6/30/2021 |
| SRI International | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| Southern Research | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| University of Pittsburgh | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| IITRI | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| Mayo Clinic | Lexi Hudak | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 7/1/2014 - 6/30/2021 |
| Battelle | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| SRI | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| Southern Research Institute | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| UIC | Randall Tiqui | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 7/1/2016 - 6/30/2021 |
| Ganges, Mary Bruce Biological Research Consultant | Jolomi Omatete | Tissue Culture technician support p to 9000 hours with a minimum of 1400 hours | 8/20/2016 - 8/19/2021 |
| Vignet | Michael Apata | This contract shall provide technical services to the Applied Research Program (ARP), in the Division of Cancer Control and Population Sciences (DCCPS) within the National Cancer Institute (NCI). ARP has needs for developmental and technical services in a broad range of content areas, including cancer-associated health behaviors, health services, and outcomes from cancer treatment. Within each of these content areas, common needs are for study management, questionnaire development, and database development and management | 9/12/2014 - 9/11/2021 |
| CDM Group | Michael Apata | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 9/12/2014 - 9/11/2021 |
| Gunnison | Michael Apata | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 9/12/2014 - 9/11/2021 |
| Vsolvit | Michael Apata | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 9/12/2014 - 9/11/2021 |
| Vanderbilt University Medical Center | Miguel Diaz | Laboratory Testing Services for Circulating Inflammation Markers and Prospective Risk of Gastric Cancer Related to the H Pylor | 9/14/2016 - 9/13/2021 |
| D's Ventures LLC, dba LOGMET | Megan Kisamore | Procurement of Gardasil-9 Vaccines in support of NCI/CCR | 9/18/2018 - 9/18/2021 |
| Invitae Corporation | David Romley | Lab Testing/Dicer I Genetic Testing | 9/19/2016 - 9/21/2021 |
| American Type Culture Collection | Rukshani Levy | The Contractor shall provide Molecular Epidemiology Assay Support (MEAS) to the Division of Cancer Epidemiology and Genectics. | 5/6/2017 - 3/5/2022 |
| Metabolon, Inc. | Rukshani Levy | The Contractor shall provide metabolomic profiling services for DCEG studies using liquid chromatography and gas chromatography mass spectrometry (LC-MS). | 6/14/2017 - 6/13/2022 |
| MRIGlobal | Junli Collins | Analysis of bulk drug samples and their pharmaceutical formulations |
8/1/2017 - 7/31/2022 |
| RTI International | Junli Collins | Analysis of bulk drug samples and their pharmaceutical formulations |
8/1/2017 - 7/31/2022 |
| SRI International | Junli Collins | Analysis of bulk drug samples and their pharmaceutical formulations |
8/1/2017 - 7/31/2022 |
| Nationwide Children's Hospital | Wilkison, Paula | Biospcimen Core Resource (BCR) | 8/25/2017 - 8/24/2022 |
| Bizzell Group | Park, Linda | Tobacco Control Research Scientific and Technical Services Support | 9/1/2017 - 8/31/2022 |
| Bayer Healthcare LLC | Jolomi Omatete | BPX30 Disposable Endorectal Coils for 3.OT MRI Scanner | 9/10/2017 - 9/17/2022 |
| Genepria Consulting Inc. | Jolomi Omatete | Statistical and Programming Appplications | 9/12/2017 - 9/11/2022 |
| Alchem | Christine Biser | Synthesis of Non-GMP Small Molecules | 9/18/2017 - 9/17/2022 |
| Connecticut Department of Public Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | |
| ASE Direct Inc. | Adam Hernandez | Erlotinib Tablets | 1/24/2020 - 1/23/2023 |
| Fundacion INCIENSA | Tom Conroy | Evaluation of Single Dose Protection Afforded by the Prophylactic HPV vaccines | 8/1/2017 - 7/31/2023 |
| Medidata Solutions | Pooja Rathore | Rave Hosting, Maintenance, and Professional Services, and License, Hosting, Maintenance, and Professional Services for Rave integrated anicillary services. | 9/1/2018 - 8/31/2023 |
| Synergy | Randall Tiqui | NCI Center for Global Health, Logistics, Data Analysis and Technical Support | 9/17/2018 - 9/16/2023 |
| IIT Research Institute | Mike Collins | PREVENT Preclinical Drug Development Program (Efficacy Pool) | 1/25/2019 - 1/24/2024 |
| SRI International | Mike Collins | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| Illinois Univ, TRL | Christy Hunter | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| University of Texas, MD Anderson | Christy Hunter | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| The Research Institute of Fox Chase Cancer Center | Christy Hunter | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| IIT Research Institute | Mike Collins | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 1/25/2019 - 1/24/2024 |
| SRI International | Mike Collins | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 1/25/2019 - 1/24/2024 |
| Illinois Univ, TRL | Christy Hunter | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 1/25/2019 - 1/24/2024 |
| Southern Research Institute | Christy Hunter | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 1/25/2019 - 1/24/2024 |
| University of Alabama at Birmingham | Mike Collins | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| University of Oklahoma Health Sciences Center | Mike Collins | PREVENT Efficacy studies | 1/25/2019 - 1/24/2024 |
| Leidos Biomedical Research | Scott Keasey | The Contractor shall, in accordance with the provisions of this contract, support the missions and programs assigned under contract with the National Cancer Institute and manage and operate the National Cancer Institute’s Federally Funded Research and Development Center (FFRDC)/Frederick National Laboratory for Cancer Research (FNLCR). The purpose of the FFRDC is to provide a unique biomedical research and development resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis, and treatment of cancer, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), and other diseases in support of the NCI, NIAID, other NIH ICs and other government agencies. The FFRDC serves as a flexible, quick-response mechanism to accomplish the most urgent national/global health initiatives for the NCI/NIH and other government agencies. | 6/26/2019 - 6/25/2024 |
| Carl Zeiss | Miguel Diaz | Maintenance Service Support for Zeiss Confocal and Epifluorescence Microscopes at the NCI CCR Microscopy Core Facilities. | 8/1/2019 - 7/31/2024 |
| Advanced Bioscience Laboratories | Megan Osele | PREVENT Preclinical Drug Development Program: CGMP Production of Vaccines and Biologicals for Cancer Prevention | 8/14/2019 - 1/24/2024 |
| International AIDS Vaccine Initiative | Megan Osele | PREVENT Preclinical Drug Development Program: CGMP Production of Vaccines and Biologicals for Cancer Prevention | 8/14/2019 - 1/24/2024 |
| Kindred Biosciences | Megan Osele | PREVENT Preclinical Drug Development Program: CGMP Production of Vaccines and Biologicals for Cancer Prevention | 8/14/2019 - 1/24/2024 |
| The University of North Carolina at Chapel Hill | Randall Tiqui | NCI's Genomics Characterization Center | 8/31/2019 - 8/30/2024 |
| University of California | Randall Tiqui | NCI's Genomics Characterization Center | 8/31/2019 - 8/30/2024 |
| Washington University in St. Louis | Randall Tiqui | NCI's Genomics Characterization Center | 8/31/2019 - 8/30/2024 |
| The Broad Institute, Inc | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| Genewiz, LLC | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| New York Genome Center | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| University of North Carolina at Chapel Hills | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| University of Southern California | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| Washington University | Lexi Hudak | NCI's Genomic Characterization Center IDIQ Contract | 8/31/2019 - 8/30/2024 |
| Roche Diagnostics Corporation | Jolomi Omatete | BenchMark Ultra Reagents and Consumables | 9/22/2019 - 9/21/2024 |
| PBG Consulting LLC | Junli Collins | NCI CSSI Technical, Programmatic and Other Support Services | 7/15/2020 - 7/14/2025 |
| 5/1/2018 - 4/30/2028 | |||
| Emory University | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Fred Hutchinson Cancer Research Center | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Health Research, Inc. | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Idaho Hospital Association | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Louisiana State University | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Massachusetts Department of Public Health | Angela Moore | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Public Health Institute | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Cancer Prevention Institute of California (CPIC) | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Hawaii | Chris Mills | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Iowa | Chris Mills | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Kentucky (Research Foundation) | Chris Mills | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of New Mexico | Chris Mills | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Southern California | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| University of Utah | Chris Mills | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Wisconsin Department of Health Services | Chris Mills | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| UCSF | Kate Muir | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 5/1/2018 - 4/30/2028 |
| Kaiser Foundation Hospitals | Nikki Arena | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| Henry Ford Health System | Erica Rosario | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| Sanford Research | Erica Rosario | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |
| The University of Chicago | Nikki Arena | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 6/4/2018 - 6/3/2028 |